Targeting Epidermal Growth Factor Receptor by means of monoclonal antibodies (moAbs) (i.e., cetuximab and panitumumab) that inhibit endogenous ligands’ binding and thus lead to the inhibition of downstream signaling pathways, both as monotherapies or in combination with a chemotherapy backbone, allowed achieving clinically relevant therapeutic advances in metastatic colorectal cancer (mCRC) patients [1,2,3,4]. The gene discussed is EGFR; the disease is metastatic colorectal cancer.